Rani Therapeutics Holdings Inc
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
RANI$0.57+5.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses | ||
| Research and development | $39,624 | $36,607 |
| General and administrative | 26,475 | 26,844 |
| Total operating expenses | $66,099 | $63,451 |
| Loss from operations | (66,099) | (63,451) |
| Other income (expense), net | ||
| Interest income and other, net | 3,301 | 1,248 |
| Interest expense and other, net | (5,085) | (1,071) |
| Loss before income taxes | (67,883) | (63,274) |
| Income tax expense | — | (70) |
| Net loss | $(67,883) | $(63,344) |
| Net loss attributable to non-controlling interest | (33,913) | (32,756) |
| Net loss attributable to Rani Therapeutics Holdings, Inc. | $(33,970) | $(30,588) |
| Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc., basic and diluted | $(1.33) | $(1.28) |
| Weighted-average Class A common shares outstanding—basic and diluted | 25,505 | 23,817 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.